Correlation of sera TNF-α with percentage of bone marrow plasma cells, LDH, β 2 -microglobulin, and clinical stage in multiple myeloma

Medical Oncology

Volumn 19, Issue 3, 2002, Pages 133-139

  Jurišić, Vladimir ^a   Čolović, Milica ^b  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Clinical stage; Lactate dehydrogenase; Multiple myeloma; TNF ; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; LACTATE DEHYDROGENASE; TUMOR NECROSIS FACTOR ALPHA; FIBRINOGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; COMPARATIVE STUDY; ERYTHROCYTE SEDIMENTATION RATE; METABOLISM; MIDDLE AGED; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; BLOOD SEDIMENTATION; BONE MARROW CELLS; FEMALE; FIBRINOGEN; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOLYSIS; PLASMA CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036434739     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:3:133     Document Type: Article

References (20)

1. Durie, B.M.G. and Salmon, S.E. (1975). A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36, 842-849.
2. Berenson, J.R., Sjak-Shie, N.N. and Vescio, R.A. (2000). The role of human and viral cytokines in the pathogenesis of multiple myeloma. Semin. Cancer Biol. 10, 383-391.
3. Greipp, P.R. and Kyle, R.A. (1996). Staging, kinetics, and prognosis of multiple myeloma, in: Neoplastic Disease of the Blood (Wiernik, P., Canelos, G., Ducher, J. and Kyle, R., (eds), pp537-559, Churchill Livingstone, New York.
4. Hallek, M., Bergsagel, P.L. and Anderson, K.C. (1998). Multiple myeloma: Increasing evidence for a multiple transformation process. Blood 91, 3-21.
5. Hatzoglou, A., et al. (2000). TNF receptor family member BCMA (B cell maturation) associated with TNF receptor-associated factor (TRAF) TRAF 2, and TRAF3, and activates NF-kappa B, elk-1, c-Jun N terminal kinase, and p38 mitogen activated protein kinase. J. Immunol. 165, 1322-1330.
6. Dunn, T.M., Wormsley, S., Taub, F.E. and Pontzer, C.H. (2000). Increased T cell cytotoxicity by Betathine-induced upregulation of TNF-alpha. Int. J. Immunopharmacol. 22, 213-227.
7. Borset, M., et al. (1999). A apoptosis, proliferation and NF-kB activation induced by agonist Fas antibodies in the human myeloma cell line OH-2: Amplification of Fas-mediated apoptosis by tumor necrosis fctor. Eur. J. Haematol. 63, 345-353.
8. Hata, M., Matsuzaki, K. and Tkatsuki, K. (1990). Autocrine growth by two cytokines, interleukin 6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Hematol. 83, 133-136.
9. Borset, M., Vaage, A., Brekke, O.L. and Helseth, E. (1994). TNF and IL-6 are potent growth factor for OH-2, a novel human myeloma cell line. Eur. J. Hematol. 53, 31-35.
10. Pisa, P., Stenke, L., Bernell, P., Hansson, M. and Hast, R. (1990). Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients. Anticancer Res. 10, 817-820.
11. Usnarska-Zubkiewicz, L. (1998). Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma. Pol. Arch. Med. Wewn. 1, 30-37.
12. Desser, L., Sakalova, A., Zavdova, E., Holomanova, D. and Mohr, T. (1997). Concentration of soluble tumor necrosis factor receptor, β2-microglobulin, IL-6, and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme-chemotherapy. Int. J. Immunother. 13, 121-130.
13. Verhoef, G.E., de Shower, P., Ceuppens, J.L., Van Damme, J., Goossens, W. and Boorgaerts, M.A. (1992). Measurement of serum cytokine level in patients with myelodisplastic syndromes. Leukemia 6, 1268-1272.
14. Jurišić, V., Spužić, I., and Konjević, G. (1999). A comparison of the NK cell cytotoxicity with effects of TNF-alpha against K-562 cells, determined by LDH release assay. Cancer Lett. 138, 67-72.
15. Decker, T. and Lohmann-Matthes, M.L. (1988). A quick and simple method for the quantification of lactate dehydrogenase release in measurements of cellular cutotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 115, 61-69.
16. Jourdan, M., et al. (1999). Tumor necrosis factor is survival and proliferation factor for human myeloma cells. Eur. Cytok. Network 10, 65-70.
17. Jurišić, V., Konjević, G., Banićević, B., Djuričić, B., and Spužić, I. (2000). Different alterations in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin's and non-Hodgkin's lymphomas. Eur. J. Haematol. 64, 259-266.
18. Rodon, P., et al. (2001). Multiple myeloma in elderly patients: Presenting and features and outcome. Br. J. Haematol. 66, 11-17.
19. Davies, F.E., et al. (2000). High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J. Clin. Oncol. 18, 2843-2851.
20. Dring, A.M., et al. (2001). Interleukin 6 tumor necrosis factor and lymphotoxin polymorphism in monoclonal gammopathy of uncertain significance and multiple myeloma. Br. J. Haematol. 112, 249-250.